Fri, Jul 25, 2014, 8:46 AM EDT - U.S. Markets open in 44 mins.


% | $
Click the to save as a favorite.

Isis Pharmaceuticals, Inc. Message Board

  • faosto faosto Jun 20, 2014 2:17 PM Flag

    It's reasonable I think to expect a buyout this year.

    With the CEO saying that ISIS's drug ISIS-APOCIIIRx that targets the APOC3 protein to reduce triglyceride levels by up to 71% "is the most important drug in our pipeline," with positive phase 2 data coming on the back of the Thrombosis drug and the diabetes drug, my guess is Biogen, which already has a partnership with ISIS, will buy them out for about $75 a share, or over $8 billion. Could go as high as $10 billion. This is reminiscent of Pharmacett, except that ISIS has at least three multi-blockbuster drugs in development. Hopefully they didn't grant too many rights to ALNY in that collaboration deal, but ISIS has a goldmine.

    Abbott could be another suitor, since they also have a deal with Biogen who in turn has a partnership with ISIS, and they have a strong cardiovascular division.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
30.62-0.77(-2.45%)Jul 24 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.